^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BPI-371153

    i
    Other names: BPI-371153, BPI 371153, BPI371153
    Associations

    News

    Trials
    Company:
    Betta Pharma
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    10ms
    A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma (clinicaltrials.gov)
    P1, N=110, Recruiting, Betta Pharmaceuticals Co., Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Jun 2025 --> Apr 2027 | Trial primary completion date: Jun 2024 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    BPI-371153
    over3years
    A Phase 1 Study of BPI-371153 in Subjects With Advanced Solid Tumors or Relapsed/Refractory Lymphoma (clinicaltrials.gov)
    P1, N=110, Not yet recruiting, Betta Pharmaceuticals Co., Ltd.
    New P1 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    BPI-371153